CN1107503C - 一种旋光纯化合物的药用 - Google Patents

一种旋光纯化合物的药用 Download PDF

Info

Publication number
CN1107503C
CN1107503C CN99118539A CN99118539A CN1107503C CN 1107503 C CN1107503 C CN 1107503C CN 99118539 A CN99118539 A CN 99118539A CN 99118539 A CN99118539 A CN 99118539A CN 1107503 C CN1107503 C CN 1107503C
Authority
CN
China
Prior art keywords
methoxyl group
salt
methyl
dimethyl
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN99118539A
Other languages
English (en)
Other versions
CN1259346A (zh
Inventor
P·L·林德堡
S·冯昂格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1107503(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Publication of CN1259346A publication Critical patent/CN1259346A/zh
Application granted granted Critical
Publication of CN1107503C publication Critical patent/CN1107503C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)

Abstract

一种旋光纯化合物在制备治疗胃肠疾病的药物中的应用，所述化合物选自(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+、Mg2+、Li+、K+、Ca2+和N+(R)4盐，其中R为有1～4个碳原子的烷基。

Description

一种旋光纯化合物的药用
本申请是1994年5月27日提交的、题为“旋光纯的吡啶甲基亚磺酰基-1H-苯并咪唑类化合物的盐”的PCT发明专利申请的分案申请(1995年1月27日进入中国国家阶段)，原申请的申请号为94190335.4。
本发明涉及一种旋光纯化合物在制备治疗胃肠疾病的药物中的应用，所述化合物选自(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+、Mg2+、Li+、K+、Ca2+和N+(R)4盐，其中R为有1～4个碳原子的烷基。
EP5129和EP124495中分别讲述了俗名为奥美拉唑的化合物，即5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑，以及其治疗学上适用的碱性盐。奥美拉唑及其碱性盐是有效的胃酸分泌抑制剂，它们可用作抗溃疡剂。该化合物由于是亚砜类化合物，在其硫原子上具有不对称中心，即存在两种旋光异构体(对映体)。人们希望制得具有改善的药代动力学和代谢特性的化合物，这种化合物应能产生改善的治疗特性，例如更低的个体间差异程度。本发明提供了这样的化合物，它们是新的奥美拉唑单一对映体的盐。
1990年的<<色谱杂志>>(J.Chromatography，532(1990)，305-19)以分析规模而DE4035455以制备规模分别描述了奥美拉唑对映体的分离。后者通过利用非对映体醚，使之分离并随后在酸性溶液中水解而实现。为水解所结合的基团，需要酸性条件，而在这种酸性条件下，奥美拉唑非常敏感，必须用碱快速中和酸，以避免所述的酸敏感化合物的降解。在上述应用中，通过将含有浓硫酸的反应混合物加至NaOH浓溶液中，完成所述的中和操作。但该方法是不利的，因为其在局部有达到pH值为1～6的高风险，这种pH值范围会破坏所述物质。另外，立即中和将会产生热，这在大规模生产中难以操作。
另一方面，本发明提供了大规模制备本发明新化合物的新方法。这种新方法还可用于以中性形式大规模制备奥美拉唑单一对映体。
先有技术中不权没有任何实例涉及旋光纯的奥美拉唑(即奥美拉唑的单一对映体)的任何分离的或特征化的盐，而且也没任何实例涉及任何旋光纯的奥美拉唑类似物的任何分离的或特征化的盐。
发明的详细描述
本发明涉及新的奥美拉唑单一对映体的Na+、Mg2+、Li+、K+、Ca2+和N+(R)4盐，其中R为有1-4个碳原子的烷基。也就是说本发明涉及(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑和(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+、Mg2+、Li+、K+、Ca2+和N+(R)4盐，其中R为有1-4个碳原子的烷基。
本发明尤其优选的盐是旋光纯的奥美拉唑的Na+、Ca2+和Mg2+盐，即(+)-5-甲氧基-2-[[(4-甲氧基-3，5-＝甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钠盐、(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钠盐、(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑镁盐、(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑镁盐、(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钙盐和(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺  酰基]-1H-苯并咪唑钙盐。
本发明最优选的盐是根据化合物Ia和Ib的旋光纯的奥美拉唑Na+盐
Figure C9911853900051
                Ia(+)-对映体
                Ib(-)-对映体以及根据化合物IIa和IIb的旋光纯的奥美拉唑镁盐
Figure C9911853900052
                IIa(+)-对映体
                IIb(-)-对映体
术语“旋光纯的奥美拉唑Na+盐”是指基本上不含有奥美拉唑Na盐(-)对映体的奥美拉唑(+)对映体，以及基本上不含有(+)对映体的奥美拉唑(-)对映体。本发明前制得的奥美拉唑单一对映体只是为浆状物而不是晶体产物。根据本发明的一个方面，通过本发明制备奥美拉唑单一对映体的新的特定方法，很容易制得本发明所定义的盐。另外，作为晶体产物制得了所述的盐，而不是中性形式。因为可以用结晶法纯化奥美拉唑对映体的不纯盐，因此即使从旋光污染的制备产物中，也可以以非常高的旋光纯度(即≥99.8％对映体过量(e.e.))制得其对映体盐。另外，该旋光纯的盐在中性pH和碱性pH中对外消旋化作用均是稳定的，这是令人惊异的，因为原认为在碱性条件下吡啶环和手性硫原子间的碳原子上的去质子化作用会引起外消旋化作用。这种对外消旋化作用的高度稳定性使得在治疗学上可应用本发明的单一对映体。
如上所述，奥美拉唑单一对映体的特定制备方法是本发明的另一方面，该方法可用于制得中性形式的奥美拉唑单一对映体及其盐。
本发明化合物可用于抑制哺乳动物及人的胃酸分泌。更广泛的意义是，本发明化合物可用于治疗哺乳动物及人的与胃酸有关的疾病和胃肠炎性疾病，例如胃溃疡、十二指肠溃疡、消化性食管炎、以及胃炎。另外，本发明化合物还可用于治疗其中需要抗胃酸分泌作用的其它胃肠疾病，例如用于正进行非甾体抗炎药(NSAID)治疗的患者、胃泌素瘤患者、急性上消化道出血患者。本发明化合物还可用于特护情形的患者，在手术前和手术后防止酸吸出并刺激溃疡。本发明化合物还可用于治疗和预防哺乳动物(包括人)的炎症，尤其是涉及溶菌酶的炎症。可特别提到的症状是类风湿性关节炎和痛风。本发明化合物还可用于治疗牛皮癣和螺旋菌(Helicobacter)感染。
本发明的还一方面是在特定的制备方法中使用的下式中间体化合物III。 制备
本发明的旋光纯化合物，即单一对映体，可按下述方法制得：分离下面式IV的5-或6-甲氧基-2-[[4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1-[酰氧基甲基]-1H-苯并咪唑的非对映体混合物的两个立体异构体，然后在碱性溶液中将分离到的每个非对映体进行溶剂分解。然后通过用中和试剂(它可以是酸或酯如甲酸甲酯)中和奥美拉唑单一对映体盐的水溶液，分离所形成的奥美拉唑单一对映体。其中苯并咪唑部分上中的甲氧基取代基位于其5和6位，酰基如下文所定义。
非对映体酯的酰基部分可以是手性酰基例如扁桃酰基，且手性酰基的不对称中心可以是R构型或者S构型。
非对映体酯可通过色谱法或分级结晶法分离。
溶剂分解作用通常是与碱一起在质子传递溶剂例如醇或水中进行，但是在非质子传递溶剂例如二甲亚砜或二甲基甲酰胺中，用碱也可水解掉该酰基。反应的碱可以是OH-或R1O-，其中R1可以是任何烷基或芳基。
为制备本发明的旋光纯Na+盐，即奥美拉唑单一对映体的钠盐，将形成的化合物用碱例如NaOH在水或非水介质中处理，或者用NaOR2(其中R2为含有1-4个碳原子的烷基)或用NaNH2处理。其中阳离子为Li+或K+的碱性盐还可用上述提到的碱的锂或钾盐制备。为制备晶形的本发明Na+盐，优选加入非水介质(例如2-丁酮和甲苯混合物)中的NaOH。
为制得本发明的旋光纯Mg2+盐将旋光纯Na+盐用无机镁盐(例如MgCl2)的水溶液处理，因此沉淀出Mg2+盐。通过在非水溶剂例如醇(仅用于醇盐)如ROH中或在醚例如四氢呋喃中用碱例如Mg(OR3)2(其中R3为含有1-4个碳原子的烷基)处理奥美拉唑的单一对映体，也可以制备旋光纯Mg2+盐。以类似的方法，使用无机钙盐(例如CaCl2)的水溶液还能制备其中阳离子为Ca2+的碱性盐。
如上所述，本发明的单一对映体的碱性盐除了钠盐(化合物Ia和Ib)和镁盐(化合物IIa和IIb)之外，还可以例举它们与Li+、K+、Ca2+、和N+(R)4的盐，其中R为有1-4个碳原子的烷基。
用于临床用途时，将本发明单一对映体即旋光纯化合物配制成适于口服、直肠、非胃肠或其它给药方式的药物制剂。该药物制剂含有本发明的单一对映体并通常组合有药学上适用的载体。载体可以是固态、半固态或液态稀释剂，或者是胶囊。这些药物制剂是本发明的另一目的。通常活性化合物的剂量占制剂总重量的0.1～95％，非胃肠道给药的制剂中为0.2～20％，口服给药的制剂中为1～50％。
在口服给药的剂量单元形式的药物制剂制备中，可以将旋光纯化合物与固体粉末载体(例如乳糖、蔗糖、山梨糖醇、甘露糖醇、淀粉、支链淀粉、纤维素衍生物、明胶或其它适用载体)、稳定剂例如碱性化合物(如钠、钾、钙、镁等的碳酸盐、氢氧化物和氧化物等等)以及润滑剂(例如硬脂酸镁、硬脂酸钙、硬脂酰富马酸钠和聚2二醇蜡)混合。然后将混合物制成颗粒或压制成片。可以用肠溶包衣材料将颗粒和片包衣，在剂型停留在胃内期间，这种肠溶包衣能保护活性化合物免遭酸催化降解。这种肠溶包衣选自药学上适用的肠溶包衣材料例如蜂蜡、虫胶、阴离子成膜聚合物等，优选时可与适用的增塑剂组合。为了区别片剂或颗粒剂中存在的活性化合物的不同剂量，可在包衣中加入各种染料。
用含有活性化台物、植物油、脂肪、或软明胶胶囊剂适用的其它载体的胶囊制备软明胶胶囊剂。也可将软明胶胶囊剂如上所述进行肠溶包衣。
硬明胶胶囊剂可含有活性化合物的颗粒或肠溶包衣颗粒。硬明胶胶囊剂还可含有与活性化合物一起组合的固体粉末载体例如乳糖、蔗糖、山梨糖醇、甘露糖醇、土豆淀粉、支链淀粉、纤维衍生物或明胶。该胶囊剂可如上所述进行肠溶包衣。
直肠给药的剂量单元可配制成栓剂形式，其中含有与中性脂肪基质混合的活性物质；或者这种剂量单元可配制成明胶直肠胶囊剂，其中含有与植物油、石蜡油或明胶直肠胶囊剂适用的其它载体混合的活性物质；或者可配制成微灌肠剂现成品形式；或者配制成微灌肠剂干粉形式，在给药前再在合适的溶剂中重新配制。
口服给药的液体制剂可配制成糖浆剂或悬浮液剂的形式，例如含有0.2～20％(重量)活性成分的溶液剂或悬浮液剂，制剂的其余成分由糖或糖醇以及乙醇、水、甘油、丙二醇和/或聚乙二醇的混合物组成。必要时，这种液体制剂可含有着色剂、调味剂、糖精和羧甲基纤维素或其它增稠剂。口服给药的液体制剂还可配制成干粉形式，在使用之前再用合适的溶剂重新配制。
非胃肠道给药的溶液剂可配制成本发明旋光纯化合物在药学适用的溶剂中的溶液剂，优选浓度为0.1～10％(重量)。这些溶液剂还可含有稳定剂和/或缓冲剂，并可制于不同的单元剂量安瓿或小瓶中。非胃肠道给药的溶液剂还可配制成干粉制剂，在使用前再用合适的溶剂即时重新配制。
活性化合物的一般日剂量将取决于各种因素，例如每一患者的个体需要、给药途径和疾病。一般情况下，每天口服和非胃肠道给药剂量为5～500mg活性化合物。
通过下面的实施例进一步阐明本发明。
                       实施例1
(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钠盐的制备
搅拌下将100mg(0.3mmol)(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑(其中含有3％(-)-异构体)溶解在1ml 2-丁酮中。加入60μl 5.0M氢氧化钠水溶液和2ml甲苯。所形成的混合物是非均相似的。为制得透明溶液，加入更多的2-丁酮(约1ml)并将混合物在环境温度下搅拌过夜。过滤所形成的沉淀并用乙醚洗涤。制得51mg(46％)标题化合物白色晶体，m.p.(分解)246-248℃。手性柱色谱法分析的旋光纯度(e.e.)≥99.8％。[α]D 20＝+42.8°(c＝0.5％，水)。表1中给出NMR数据
                   实施例2(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钠盐的制备
搅拌下将100mg(0.3mmol)(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑(其中含有3％(+)-异构体)溶解在1ml 2-丁酮中。加入60μl 5.0M氢氧化钠水溶液和2ml甲苯。形成的混合物是非均相的。为制得透明溶液，加入更多的2-丁酮(约1ml)并将混合物在环境温度下搅拌过夜。过滤所形成的沉淀并用乙醚洗涤。制得56mg(51％)标题化合物白色结晶，m.p.(分解)247-249℃。手性柱色谱法分析的旋光纯度(e.e.)≥99.8％[α]D 20＝-44.1°(c＝0.5％水)。NMR数据见表1 。
                  实施例3
(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑镁盐的制备
将2.9ml 0.1M NaOH溶液加至0.10g(0.29mmol)(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑中。向该混合物中加入2ml二氧甲烷，在分液漏斗中混合后，分离掉水溶液。滴加14mg(0.145mmol)MgCl2在水中的溶液。形成的沉淀经离心分离，分离得到52mg(50％)产物，为非晶形粉末。旋光纯度(e.e.)为98％，与原料相同。旋光纯度是在分析用手性柱上经色谱法测定的。[α]D 20＝+101.2(c＝1％，甲醇)。原子吸收光谱法测定样品Mg含量为3.0％。
                  实施例4(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑镁盐的制备
将(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钠盐(0.500g，1.36mmol)溶解在水(10ml)中。向该混合物中滴加10ml MgCl2.xH2O(138mg，0.68mmol)水溶液，形成的沉淀经离心分离。制得418mg(86％)产物，为白色粉末。产物的旋光纯度(e.e.)为99.8％，与原料的旋光纯度相同。旋光纯度是在分析用手性柱上经色谱法测定的。[α]D 20＝+129.9°(c＝1％，甲醇)。
                   实施例5(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺，酰基]-1H-苯并咪唑镁盐的制备
将(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺，酰基]-1H-苯并咪唑钠盐(0.165g，0.45mmol)溶解在水(3ml)中。向该混合物中滴加2ml MgCl2.xH2O(46mg，0.23mmol)水溶液，形成的沉淀经离心分离。制得85mg(51％)产物，为白色粉末。产物的旋光纯度(e.e.)为99.9％，与原料的旋光纯度相同或更好。旋光纯度是在分析用手性柱上经色谱法测定的。[α]D 20＝-128.2°(c＝1％，甲醇)。表1：实施例编号                       NMR数据         δppm
1.DMSO-d6   2.20(s，3H)，2.22(s，3H)，3.69(s，3H)，3.72(s，3H)，4.37
  500MHz    (d.1H)，4.75(d，1H)，6.54(dd，1H)，6.96(d，1H)7.30(d，
            1H)，8.21(s，1H).
2.DMSO-d6   2.20(s，3H)，2.22(s，3H)，3.69(s，3H)，3.72(s，3H)，
  500MHz    4.38(d，1H)，4.73(d，1H)，6.54(dd，1H)，6.96(d，1H)，7.31
            (d，1H)，8.21(s，1H).
下面实施例将说明本发明合成的中间体的制备。
                      实施例66-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-(R/S)-亚磺酰基]-1-[(R)-扁桃酰氧基甲基]-1H-咪唑的制备
将3.4g氢氧化钠在40ml水中的溶液加至14.4g(42mmol)硫酸氢(四丁基)铵和6.4g(42mmol)(R)-(-)扁桃酸的混合物中。用400ml氯仿萃取混合物。分离后，将有机萃取物与16.6g(42mmol)6-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-亚磺酰基]-1-[氧甲基]-1H-苯并咪唑的外消旋体-起加热至回流。溶剂蒸发后，用100ml二氯甲烷和700ml乙酸酯稀释。混合物用3×200ml水洗涤，有机溶液用MgSO4干燥然后蒸馏。粗品在100ml乙腈中用重结晶法纯化，得到8.1g标题化合物(38％)，为非对映体混合物。表2中给出NMR数据。
                   实施例76-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-(R/S)-亚磺酰基]-1-[(R)-扁桃酰氧基甲基]-1H-苯并咪唑的较亲水性非对映体的分离。
用反相色谱法(HPLC)分离实施例6中标题化合物的非对映体。将约300mg对映体混合物溶解在10ml热乙腈中，用10ml 0.1M乙酸铵水溶液和乙腈(70/30)的混合物稀释。将溶液注入柱中并用0.1M乙酸铵水溶液和乙腈(70/30)的混合物洗脱化合物。与亲水性差的异物体相比，更亲水的异构体较易制得纯品。按下法进行含有纯异物体的级份的后处理步骤：用二氯甲烷萃取，用5％碳酸氢钠水溶液洗涤有机溶液，用Na2SO4干燥并在旋转蒸发仪上蒸馏溶剂(在蒸馏结束时，通过加入更多的二氯甲烷，便于乙腈的除去)。用上述技术，使用1.2g非对映体混合物，制得纯的较亲水性异构体410mg，为无色浆状。表2中给出NMR数据。
                   实施例86-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-(R/S)-亚磺酰基]-1-[(S)-扁桃酰氧基甲基]-1H-苯并咪唑的制备
用实施例6相同的方法，由8.1g(202mmol)氢氧化钠在100ml水中的溶液与34.4g(101mmol)硫酸氢(四丁基)铵、15.4g(101mmol)(S)-(+)-扁桃酸和39.9g(101mmol)6-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-亚磺酰基]-1-[氯甲基]-1H-萃并咪唑的外消旋体反应制得该产物。在100ml乙腈中重结晶，得到21.3g(41％)标题化合物，为非对映体混合物。表2中给出NMR数据。
                   实施例96-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-(R/S)-亚磺酰基]-1-[(S)-扁桃酰氧基甲基]-1H-苯并咪唑的较亲水性非对映体的分离。
用反相色谱法(HPLC)，以实施例7的相同方法分离实施例8的标题化合物的非对映体，但用6-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]-(R/S)-亚磺酰基]-1-[(S)-扁桃酰氧基甲基]-1H-苯并咪唑的非对映体混合物代替实施例7中使用的(R)-扁桃酸酯。使用2.1g非对映体混合物，制得760mg纯的较亲水性异构体，为无色浆状物。表2中给出NMR数据。
                   实施例10(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的制备
将0.23g(0.45mmol)6-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1-[(R)-扁桃酰氧基甲基]-1H-苯并咪唑的较亲水性非对映体溶解在15ml甲醇中。加入36mg(0.9mmol)氢氧化钠在0.45ml水中的溶液，10分钟后在旋转蒸发仪上蒸馏混合物。残余物在15ml水和15ml二氧甲烷之间分配。有机溶液用15ml水萃取，并向合并的水溶液中加入85μl(1.4mmol)甲酸甲酯。15分钟后混合物用3×10ml二氯甲烷萃取。有机溶液用Na2SO4干燥，然后蒸馏。制得0.12g(77％)标题化合物，为无色浆状物。用手性柱色谱法分析的旋光纯度(e.e.)为94％。[α]D 20＝-155°(c＝0.5％，氯仿)。表2中给出NHR数据。
                     实施例11(+)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的制备
将0.76g 6-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1-[(S)-扁桃酰氧基甲基]-1H-苯并咪唑的较亲水性非对映体溶解在50ml甲醇中。加入0.12mg(3.0mmol)氧氧化钠在1.5ml水中的溶液，10分钟在旋转蒸发仪上蒸馏混合物。残余物在25ml水和25ml二氯甲烷之间分配。有机溶液用25ml水萃取，并向合并的水溶液中加入200μl(3.2mmol)甲酸甲酯。15分钟后混合物用3×25ml二氧甲烷萃取。有机溶液用Na2SO4干燥然后蒸馏。制得0.42g(81％)标题化合物，为无色浆状物。用手性柱色谱法分析的旋光纯度(e.e.)为98％。[α]D 20＝+157°(c＝0.5％，氯仿)。表2中给出NMR数据。表2：实施例编号                            NMR数据δppm
6.    CDCl3     2.18(s，3H)，2.20(s，3H)，2.36(s，3H)，2.39(s，3H)，
      500MHz    3.77(s，3)，3.78(s，3H)，3.82(s，3H)，3.87(s，3H)，4.80(d，
                1H)，4.88(d，1H)，5.0(m，2H)，5.34(s，2H)，6.43(d，1H)，
                6.54(d，1H)，6.6-6.7(m，2H)，6.90(d，1H)，6.95-6.98(m，
                2H)，7.01(d，1H)，7.2-7.3(m，6H)，7.37(m，2H)，7.44(m，
                2H)，7.58(d，1H)，7.62(d，1H)，7.95(s，1H)，7.97(s，1H)。
7.    CDCl3     2.20(s，3H)，2.36(s，3H)，3.78(s，3H)，3.82(s，3H)，
      500MHz    4.80(d，1H)，5.00(d，1H)，5.35(d，1H)，6.43(d，1H)，6.63
                (d，1H)，6.90(d，1H)，6.97(dd，1H)，7.2-7.3(m，3H)，7.37
                (m，2H)，7.62(d，1H)，7.97(s，1H)。
8.    CDCl3      2.19(s，3H)，2.20(s，3H)，2.36(s，3H)，2.39(s，3H)，3.77
      500MHz     (s，3H)，3.78(s，3H)，3.83(s，3H)，3.87(s，3H)，4.80(d，1H)，
                 4.88(d，1H)，5.0(m，2H)，5.34(s，2H)，6.43(d，1H)，6.54(d，
                 1H)，6.6-6.7(m，2H)，6.90(d，1H)，6.96-6.98(m，2H)，7.01
                 (d，1H)，7.2-7.3(m，6H)，7.37(m，2H)，7.44(m，2H)，7.58(d，
               1H)，7.62(d，1H)，7.95(s，1H)，7.97(s，1H).
9.   CDCl3     2.20(s，3H)，2.36(s，3H)，3.78(s，3H)，3.82(s，3H)，4.80
     500MHz    (d，1H)，5.00(d，1H)，5.35(d，1H)，6.43(d，1H)，6.63
               (d，1H)，6.90(d，1H)，6.97(dd，1H)，7.2-7.3(M，3H)，7.37
               (m，2H)，7.62(d，1H)，7.97(s，1H).
10.  CDCl3     2.18，(s，3H)，2.22(s，3H)，3.68(s，3H)，3.83(s，3H)，
     300MHz    4.77(m，2H)，6.93(dd，1H)，＝7.0(b，1H)，＝7.5(b，1H)，8.19
               (s，1H).
11.  CDCl3     2.21(s， 3H)，2.23(s，3H)，3.69(s，3H)，3.84(s，3H)，4.76(m，
               2H)，6.94(dd，1H)，＝7.0(b，1H)，＝7.5(b，1H)，8.20(s，1H).
目前已知的实现本发明的最佳方式是使用本发明旋光纯化合物的钠盐，这些化合物描述于实施例1和实施例2中。
下面的制剂说明含有本发明化合物作为活性成分的药物制剂。糖浆剂
由下列成分配制含有1％(重量/体积)活性物质的糖浆剂：根据实施例2的化合物                            1.0g糖(粉末)                                       30.0g糖精                                           0.6g甘油                                           5.0g调味剂                                         0.05g96％乙醇                                       5.0g蒸馏水    加至最终体积为                       100ml
将糖和糖精溶解在60g温水中，冷却后向糖溶液中加入活性化合物，并加入甘油和溶解在乙醇中的调味剂溶液。将混合物用水稀释至100ml的最终体积。包有肠溶衣的片剂
由下列成分配制含有50mg活性化合物的包有肠溶衣的片剂：I.根据实施例3的化合物(作为Mg盐)              500g乳糖                                       700g甲基纤维素                                 6g交联的聚乙稀吡咯烷酮                       50g硬脂酸镁                                   15g碳酸钠                                     6g蒸馏水                                     适量II.邻苯二甲酸乙酸纤维素                      200g鲸蜡醇                                    15g异丙醇                                    2000g二氯甲烷                                  2000g
I、将根据实施例3的化合物粉末与乳糖混合并用甲基纤维素和碳酸钠的水溶液制粒。用力使湿块通过网筛，并在烘箱中干燥颗粒。干燥后将颗粒与聚乙稀吡咯烷酮和硬脂酸镁混合。在压片机中用7mm直径的冲头将干混台物压成片芯(10000片)，每片含有50mg活性物质。
II、在Accela CotaR，Hanesty包衣装置中将邻苯二甲酸乙酸纤维素和鲸蜡醇在异丙醇/二氯甲烷中的溶液喷雾于片剂I上。制得最终重110mg的片剂。静脉内给药的溶液剂
由下列成分配制每ml含有4mg活性成分的静脉内使用的非胃肠道给药的制剂：根据实施例2的化合物                             4g无菌水            加至最终体积为                1000ml
将活性化合物溶解在水中，加水至最终体积为1000ml。将溶液经0.22μm滤膜过滤并立即分装在10ml无菌安瓿中。将安瓿密封。胶囊剂
由下列成分配制含有30mg活性成分的胶囊剂：根据实施例1的化合物                            300g乳糖                                           700g微晶纤维素                                     40g低取代的羟丙基纤维素                           62g磷酸氢二钠                                     2g纯水                                           适量
将活性化合物与干成分混合并用磷酸氢二钠溶液制粒。用力使湿块通过挤压机并团成球状，然后在流化床干燥器中干燥。
用流化床包衣设备，首先将上述500g小丸用30g羟丙基甲基纤维素在750g水中的溶液包衣。干燥后，再将小丸用如下给定的第二种包衣溶液包衣。包衣溶液：羟丙基甲基纤维素邻苯二甲酸酯                      70g鲸蜡醇                                            4g丙酮                                              200g乙醇                                    600g
将最终包衣的小丸装入胶囊中。栓剂
用熔合法由下列成分分配制栓剂，每-栓剂含有40mg活性成分。根据实施例2的化合物                     4gWitepsol H-15                           180g
在41℃的温度下将活性化合物与Witepsol H-15均匀混合。将熔融体装入预制的栓剂外壳至净重为1.84g冷却后将该外壳热密封。每一栓剂含有40mg活性成分。不同pH值下对外消旋化的稳定性
在pH为8、9.3、10和12的缓冲水溶液中，于冰箱内，测定了本发明的旋光纯化合物在低浓度时对外消旋化作用的稳定性。通过比较5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)-甲基]亚磺酰基]-1H-苯并咪唑的(-)-异构体在缓冲溶液中在溶解后即刻和溶解数天后的旋光纯度，测定了其立体化学稳定性。在分析用手性柱上通过色谱法完成测定。在pH11.2时即使21天也未观察到受试化合物的任何外消旋化作用，这一事实说明了本发明化合物在减性条件下的令人惊异的高度立体化学稳定性。在pH8、9.3和10时，本发明化合物的化学降解较明显，这使得外消旋化作用的测定较难完成，但所有这些pH值条件下溶解的16天后均未检测到外消旋化作用。
在用本发明旋光纯化合物进行的另一外消旋化实验中，将5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的(+)-异构体的磷酸盐缓冲水溶液在37℃温热26小时，根本未观察到任何外消旋化作用。

Claims (8)

1.一种旋光纯化合物在制备治疗胃肠疾病的药物中的应用，所述化合物选自(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+、Mg2+、Li+、K+、Ca2+和N+(R)4盐，其中R为有1～4个碳原子的烷基。
2.根据权利要求1的应用，其中所述化合物是(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+、Mg2+或Ca2+盐。
3.根据权利要求1的应用，其中所述化合物是(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Mg2+盐。
4.根据权利要求1的应用，其中所述化合物是晶体形式的(-)-5-甲氧基-2-[[(4-甲氧基-3，5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑的Na+盐。
5.根据权利要求1-4之一的应用，用于制备抑制胃酸分泌的药物。
6.根据权利要求1-4之一的应用，用于制备治疗胃肠炎性疾病的药物。
7.根据权利要求1-4之一的应用，用于制备具有更低的个体间血浆浓度差异程度的药物。
8.根据权利要求1-4之一的应用，用于制备在治疗与胃酸有关的疾病时具有改善的治疗特性的药物。
CN99118539A 1993-05-28 1999-09-03 一种旋光纯化合物的药用 Expired - Lifetime CN1107503C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
SE9301830 1993-05-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN94190335A Division CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用

Publications (2)

Publication Number Publication Date
CN1259346A CN1259346A (zh) 2000-07-12
CN1107503C true CN1107503C (zh) 2003-05-07

Family

ID=20390088

Family Applications (2)

Application Number Title Priority Date Filing Date
CN94190335A Expired - Lifetime CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用
CN99118539A Expired - Lifetime CN1107503C (zh) 1993-05-28 1999-09-03 一种旋光纯化合物的药用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN94190335A Expired - Lifetime CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用

Country Status (43)

Country Link
US (5) US5693818A (zh)
EP (3) EP1020460B1 (zh)
JP (3) JP3549111B2 (zh)
KR (1) KR100337274B1 (zh)
CN (2) CN1055469C (zh)
AT (1) ATE197452T1 (zh)
CA (2) CA2337581A1 (zh)
CL (1) CL2009000805A1 (zh)
CY (1) CY2224B1 (zh)
CZ (1) CZ287876B6 (zh)
DE (4) DE69435220D1 (zh)
DK (3) DK1020460T3 (zh)
DZ (1) DZ1785A1 (zh)
EE (1) EE03157B1 (zh)
ES (3) ES2099047T3 (zh)
FI (2) FI117755B (zh)
GR (2) GR970300012T1 (zh)
HK (3) HK1008330A1 (zh)
HR (1) HRP940307B1 (zh)
HU (1) HU226824B1 (zh)
IL (1) IL109684A (zh)
IS (1) IS1854B (zh)
LT (1) LT3287B (zh)
LU (1) LU91870I2 (zh)
LV (1) LV11034B (zh)
MA (1) MA23210A1 (zh)
MY (1) MY121192A (zh)
NO (2) NO307378B1 (zh)
NZ (1) NZ266915A (zh)
PL (1) PL178994B1 (zh)
PT (3) PT1020461E (zh)
RU (1) RU2137766C1 (zh)
SA (2) SA05260103B1 (zh)
SE (1) SE9301830D0 (zh)
SG (1) SG49283A1 (zh)
SI (2) SI9420002B (zh)
SK (1) SK282524B6 (zh)
TN (1) TNSN94058A1 (zh)
TW (1) TW389761B (zh)
UA (1) UA60289C2 (zh)
WO (1) WO1994027988A1 (zh)
YU (1) YU49065B (zh)
ZA (1) ZA943557B (zh)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO1999053918A1 (fr) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142629A0 (en) 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
AU2878801A (en) * 1999-10-01 2001-05-10 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
WO2001028559A1 (fr) * 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DK1257269T3 (da) 2000-02-24 2005-03-14 Kopran Res Lab Ltd Syrestabile benzimidazolderivater til oral indgivelse mod ulcus
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
AU2002338655A1 (en) * 2001-04-13 2002-10-28 Aspinterm Llc Methods of preparing sulfinamide and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2445513A1 (en) 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
CA2474246C (en) * 2002-03-05 2010-06-29 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
US6897227B2 (en) * 2002-07-19 2005-05-24 Winston Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US7211590B2 (en) * 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2004020436A1 (en) 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EA200500673A1 (ru) 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
SI1575941T1 (sl) 2002-12-06 2012-08-31 Nycomed Gmbh Postopek za pripravo (S)-pantoprazola
US7452998B2 (en) 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
US20060189590A1 (en) * 2003-07-23 2006-08-24 Bernhard Kohl Alkaline salts of proton pump inhibitors
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
EP1663173A1 (en) * 2003-09-25 2006-06-07 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
WO2005105786A1 (en) 2004-04-28 2005-11-10 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
WO2006001755A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab A new esomeprazole sodium salt crystal modification
WO2006001753A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
AU2005268056B2 (en) 2004-08-06 2008-07-31 Eisai R&D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for production thereof
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
JP4837722B2 (ja) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． 置換スルホキシド化合物、その調製方法、およびその使用方法
EP1885711A1 (en) 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
WO2006134605A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
AU2006323245B2 (en) 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US7799925B2 (en) * 2005-12-28 2010-09-21 Unión Químico Farmacéutica, S.A. Process for the preparation of the (S)-enantiomer of omeprazole
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
DE602007010926D1 (de) * 2006-06-07 2011-01-13 Astrazeneca Ab Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
KR20160031040A (ko) * 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
CA2675443A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals North America, Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2114919A2 (en) * 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2678702A1 (en) 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
DK2106397T3 (da) 2007-09-25 2012-01-30 Hetero Drugs Ltd Fremgangsmåde til fremstilling af enantiomer-ren esomeprazol
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
EP3239146A4 (en) 2014-12-26 2018-05-30 The University of Tokyo Method for producing proton pump inhibitor compound having optical activity
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (en) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CN114364371A (zh) * 2019-07-16 2022-04-15 金德雷德生物科学股份有限公司 马科动物埃索美拉唑配制品及其用途
US20220306593A1 (en) 2019-08-29 2022-09-29 Tokyo University Of Science Foundation Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts

Also Published As

Publication number Publication date
WO1994027988A1 (en) 1994-12-08
SI22752A (sl) 2009-10-31
US20080312449A1 (en) 2008-12-18
EP1020461A2 (en) 2000-07-19
ES2326404T3 (es) 2009-10-09
HK1028044A1 (en) 2001-02-02
DZ1785A1 (fr) 2002-02-17
DK1020461T3 (da) 2009-08-10
EP1020460A3 (en) 2003-10-15
JP2004043493A (ja) 2004-02-12
ES2326405T3 (es) 2009-10-09
HUT71888A (en) 1996-02-28
YU49065B (sh) 2003-08-29
SA05260103B1 (ar) 2010-01-31
TW389761B (en) 2000-05-11
EP1020461A3 (en) 2006-10-04
FI950377A (fi) 1995-01-27
NO2011009I1 (no) 2011-06-20
IS1854B (is) 2003-02-21
HK1028045A1 (en) 2001-02-02
DE69426254T2 (de) 2001-06-07
PT1020461E (pt) 2009-07-29
ES2099047T1 (es) 1997-05-16
DE69435220D1 (de) 2009-09-03
RU2137766C1 (ru) 1999-09-20
NO950263L (no) 1995-01-24
MA23210A1 (fr) 1994-12-31
JP4039999B2 (ja) 2008-01-30
LTIP1941A (en) 1994-12-27
PL178994B1 (pl) 2000-07-31
IL109684A0 (en) 1994-12-29
EP1020460B1 (en) 2009-07-22
EP0652872A1 (en) 1995-05-17
DE69426254D1 (de) 2000-12-14
SK10195A3 (en) 1995-09-13
CN1110477A (zh) 1995-10-18
JP3549111B2 (ja) 2004-08-04
CL2009000805A1 (es) 2009-08-21
AU676337B2 (en) 1997-03-06
US20100222591A1 (en) 2010-09-02
CN1259346A (zh) 2000-07-12
CA2139653A1 (en) 1994-12-08
HRP940307B1 (en) 2001-06-30
EP0652872B1 (en) 2000-11-08
JP2004043494A (ja) 2004-02-12
LT3287B (en) 1995-06-26
CZ287876B6 (cs) 2001-03-14
ES2099047T3 (es) 2001-03-01
YU31494A (sh) 1997-05-28
LV11034A (lv) 1996-02-20
JPH07509499A (ja) 1995-10-19
NZ266915A (en) 1996-10-28
NO307378B1 (no) 2000-03-27
NO950263D0 (no) 1995-01-24
FI20070002A (fi) 2007-01-02
EP1020461B2 (en) 2015-10-21
CN1055469C (zh) 2000-08-16
HU9500247D0 (en) 1995-03-28
FI117755B (fi) 2007-02-15
HU226824B1 (en) 2009-11-30
ES2326405T5 (es) 2016-02-15
CZ20295A3 (en) 1995-10-18
JP3959056B2 (ja) 2007-08-15
EP1020460A2 (en) 2000-07-19
CA2337581A1 (en) 1994-12-08
KR100337274B1 (ko) 2003-12-31
DE652872T1 (de) 1997-09-04
PL307261A1 (en) 1995-05-15
SG49283A1 (en) 1998-05-18
DK1020460T3 (da) 2009-08-10
SI22752B (sl) 2010-01-29
PT652872E (pt) 2001-04-30
DK1020461T4 (en) 2016-02-15
ATE197452T1 (de) 2000-11-11
EP1020461B1 (en) 2009-07-22
ZA943557B (en) 1995-04-11
IL109684A (en) 2002-05-23
IS4161A (is) 1994-11-29
US6143771A (en) 2000-11-07
FI950377A0 (fi) 1995-01-27
US5714504A (en) 1998-02-03
PT1020460E (pt) 2009-07-29
DK0652872T3 (da) 2001-03-05
EE03157B1 (et) 1999-02-15
KR950702553A (ko) 1995-07-29
CA2139653C (en) 2001-07-10
LU91870I2 (fr) 2011-11-21
RU95105587A (ru) 1996-10-27
MY121192A (en) 2006-01-28
SI9420002A (en) 1995-08-31
HRP940307A2 (en) 1996-12-31
SA94140756B1 (ar) 2006-05-20
SE9301830D0 (sv) 1993-05-28
LV11034B (en) 1996-10-20
HK1008330A1 (en) 1999-05-07
SI9420002B (sl) 2009-12-31
US5693818A (en) 1997-12-02
CY2224B1 (en) 2003-04-18
TNSN94058A1 (fr) 1995-04-25
AU6902494A (en) 1994-12-20
SK282524B6 (sk) 2002-10-08
UA60289C2 (uk) 2003-10-15
DE69435221D1 (de) 2009-09-03
GR970300012T1 (en) 1997-05-31
GR3035365T3 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
CN1107503C (zh) 一种旋光纯化合物的药用
CN1150186C (zh) 苯并咪唑化合物结晶
US6262085B1 (en) Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6875872B1 (en) Compounds
CN1128997A (zh) 新的二烷氧基-吡啶基-苯并咪唑衍生物
CN1671691A (zh) (s)－泛托派唑的盐及其水合物
JPH09504556A (ja) 新規な置換ベンズイミダゾール
AU676337C (en) Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTRAZENCA AB

Free format text: FORMER NAME OR ADDRESS: AKTIEBOLAGET ASTRA

CP01 Change in the name or title of a patent holder

Patentee after: Astra Zeneca Aktiebolag

Patentee before: Astra Aktiebolag

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20140527

Granted publication date: 20030507